H.R. 6584 117th Congress
DEPICT Act
- Health
- Sponsor: Rep. Eshoo, Anna G. [D-CA-18]
- Congress.gov ↗
Latest action, Feb 4, 2022: Referred to the Subcommittee on Health.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
17 cosponsors
Sponsored by Rep. Eshoo, Anna G. [D-CA-18] (Democrat). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
16 D · 1 R
- Democrat
- Republican
- Independent
Referred to: House: Energy and Commerce Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
4 reports
4 reports
4 reports
BLOOD CANCER UNITED (FORMERLY REPORTED ASTHE LEUKEMIA AND LYMPHOMA SOCIETY)
KOUNTOUPES DENHAM CARR & REID, LLC
4 reports
4 reports
4 reports
4 reports
4 reports
PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC
COVINGTON & BURLING LLP
4 reports
SUSAN G. KOMEN
ARTEMIS POLICY GROUP LLC
4 reports
4 reports
All 25 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| AMERICAN ACADEMY OF FAMILY PHYSICIANS | 4 | $3.2M | Q1 2022 | Q3 2022 | yes | |
| ASSOCIATION FOR ACCESSIBLE MEDICINES | 4 | $3.2M | Q1 2022 | Q3 2022 | yes | |
| ASSOCIATION FOR CLINICAL ONCOLOGY | 4 | $575K | Q1 2022 | Q3 2022 | yes | |
| ASTRAZENECA PHARMACEUTICALS LP | 4 | $4.8M | Q1 2022 | Q3 2022 | yes | |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 4 | $13.3M | Q1 2022 | Q3 2022 | yes | |
| BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) | 4 | $700K | Q1 2022 | Q3 2022 | yes | |
| BLOOD CANCER UNITED (FORMERLY REPORTED ASTHE LEUKEMIA AND LYMPHOMA SOCIETY) | KOUNTOUPES DENHAM CARR & REID, LLC | 4 | $200K | Q1 2022 | Q3 2022 | yes |
| EMD SERONO INC | 4 | $2.2M | Q1 2022 | Q3 2022 | yes | |
| GENENTECH INC | 4 | $8.8M | Q1 2022 | Q3 2022 | yes | |
| GSK (FKA GLAXOSMITHKLINE INC.) | 4 | $4.5M | Q1 2022 | Q3 2022 | yes | |
| MERCK & CO INC | 4 | $8.3M | Q1 2022 | Q3 2022 | yes | |
| PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC | COVINGTON & BURLING LLP | 4 | $0 | Q1 2022 | Q3 2022 | yes |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 4 | $28.3M | Q1 2022 | Q3 2022 | yes | |
| SUSAN G. KOMEN | ARTEMIS POLICY GROUP LLC | 4 | $166K | Q1 2022 | Q3 2022 | yes |
| TAKEDA PHARMACEUTICALS AMERICA INC | 4 | $4.9M | Q1 2022 | Q3 2022 | yes | |
| THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH | 4 | $170K | Q1 2022 | Q3 2022 | yes | |
| THE SUSAN G. KOMEN BREAST CANCER FOUNDATION, INC. DBA SUSAN G. KOMEN | 4 | $270K | Q1 2022 | Q3 2022 | yes | |
| AMGEN INC | 3 | $8.0M | Q1 2022 | Q3 2022 | yes | |
| ASTRAZENECA | TIBER CREEK GROUP | 3 | $180K | Q4 2022 | Q3 2022 | yes |
| AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC | 2 | $3.2M | Q4 2022 | Q3 2022 | yes | |
| ASSOCIATION OF BLACK CARDIOLOGISTS | SUMMIT HEALTH CARE CONSULTING | 2 | $30K | Q4 2021 | Q1 2022 | yes |
| AUTOIMMUNE ASSOCIATION | 2 | $0 | Q4 2022 | Q3 2022 | yes | |
| BIOMARIN PHARMACEUTICAL INC. | 2 | $780K | Q1 2022 | Q2 2022 | yes | |
| NOVARTIS | 2 | $2.6M | Q4 2022 | Q3 2022 | yes | |
| UNIVERSITY OF CALIFORNIA | 2 | $500K | Q2 2022 | Q3 2022 | yes |